HGF-inhibitory macrocyclic peptide -- mechanisms and potential cancer theranostics

May 29, 2019


Hepatocyte Growth Factor (HGF)*1) is a protein that acts as a cell growth factor. By binding to its receptor protein MET on the cell membrane, it exerts its physiological functions such as proliferation and migration of cells, as well as tissue repair and regeneration. For a cancer tissue, since it promotes invasion and survival of cancer cells, it can play roles in cancer metastasis and acquisition of resistance against anti-cancer drugs. HGF exists in a precursor form, inactive HGF, in various tissues, but the precursor is converted into active HGF only in the vicinity of cancer cells. Because of this reason, molecules that selectively detect/inhibit active HGF are highly desirable but have not been described so far.

Molecular-targeted drugs that selectively inhibit specific molecules have been developed and used for cancer treatment and for other diseases. Among others, antibodies show high specificity to their target molecules, but one of their drawbacks is their very high cost. On the other hand, synthetic drugs are much less expensive since they can be chemically synthesized but their specificity against their target molecules is not high. Recently, much attention has been paid to macrocyclic peptides*2), which may show target specificity as high as antibodies and yet may be available by chemical synthesis.


The present collaborative research team from five institutions including Kanazawa University successfully discovered a macrocyclic peptide, HiP-8, which binds to the active form of HGF to inhibit its activity, using the PaPID method*3). HiP-8 is a macrocyclic peptide consisting of 12 amino acid residues in a ring-like geometry (Figure 1), binding to active HGF with a very high affinity and inhibiting HGF binding to its receptor MET (Figure 1).

In addition, in order to elucidate the functional interaction between HiP-8 and HGF, this study employed high-speed atomic force microscopy (HS-AFM)*4) developed at Kanazawa University, which allows visualization of the dynamics and morphology of biological molecules (Figure 2). This investigation successfully showed that, while an active HGF molecule exhibited dynamic behavior, upon binding of HiP-8, the molecular dynamics of HGF was strongly inhibited. This novel discovery shows that the highly dynamic nature of a protein molecule was inhibited by a small molecule.

Further, image analysis using positron emission tomography (PET)*5) and radio-labeled HiP-8, administered to mice xenografted with human lung cancer tissue, suggest a possible application of HiP-8 to cancer diagnosis. HiP-8 selectively accumulated in cancer tissue with active HGF (Figure 3), suggesting that HiP-8 should be useful as a probe for PET imaging diagnosis. Since HiP-8 inhibits HGF activity, it could also be used as an anti-cancer molecular targeted drug selective for active HGF.

Future prospects

The results of the present study are expected to lead to the development of new PET diagnostic methods with radiotracer HiP-8, a macrocyclic peptide. HiP-8 is a candidate molecule of a new molecular-targeted drug that selectively inhibits only active HGF.

Kanazawa University

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.